rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurlers Syndrome, Hurler-Scheie Syndrome
Trial Timeline
Dec 1, 2000 → Sep 1, 2001
NCT ID
NCT00912925About rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo
rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo is a phase 3 stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00912925. Target conditions include Mucopolysaccharidosis I, Hurlers Syndrome, Hurler-Scheie Syndrome.
What happened to similar drugs?
5 of 14 similar drugs in Mucopolysaccharidosis I were approved
Approved (5) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00912925 | Phase 3 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I